Jiangxi Jdl Environmental Protection Co., Ltd. (688057.SH) plans to increase its capital by RMB 30 million to invest in Zhongke Hongtai.
Jindalai (688057.SH) announced that the company is optimistic about the development prospects of national strategic emerging industries such as the research and development and application of medical robot technology and systems. It plans to gradually optimize the company's industrial structure, seek new industry opportunities for future development, improve the company's risk resistance ability, and cultivate new profit growth points. The company plans to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd. ("Zhongke Hongtai"), of which 195.86895 million yuan will be used to subscribe for 195.86895 million yuan of new registered capital of Zhongke Hongtai, and the remaining 2,804.13105 million yuan will be included in the capital reserve. After the completion of this transaction, the company will hold 10% equity in Zhongke Hongtai.
Jiangxi Jdl Environmental Protection Co., Ltd. (688057.SH) announced that, based on the optimistic outlook for the development prospects of the national strategic emerging industry of medical Siasun Robot & Automation technology and system, the company plans to gradually optimize its industrial structure, seeking new industrial opportunities for future development to enhance the company's risk resistance capabilities and cultivate new profit growth points. The company proposes to increase its investment in Beijing Zhongke Hongtai Medical Technology Co., Ltd. (referred to as "Zhongke Hongtai") by 30 million yuan, with 195.86895 million yuan used to subscribe to Zhongke Hongtai's 195.86895 million yuan of new registered capital, and the remaining 2804.13105 million yuan included in the capital surplus. After the completion of this transaction, the company will hold 10% of Zhongke Hongtai's equity.
The multi-channel vascular intervention surgery Siasun Robot & Automation developed by the target company has the following significant advantages: (1) Designed based on bionics principles, it can simultaneously rotate and push the wire; (2) The dual-channel design allows for the simultaneous operation of two wires, two balloons/stent catheters; (3) It has force feedback function. In addition to the above advantages, compared to the current industry level, the target company's Siasun Robot & Automation surgery can achieve remote surgery, full-process Siasun Robot & Automation assistance, and data collection functions.
The core team of the target company has a deep technical foundation and original research and development capabilities, with products featuring differentiated innovation and technological breakthroughs, providing a leading smart catheter room overall solution. The purpose of this external investment is to expand the company's business, enhance profitability, further improve the company's comprehensive competitiveness and influence, and promote sustainable development.
Related Articles

JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.

China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.

SUNSHINE OIL (02012) plans to discount about 10% of the rights issue, raising a maximum of approximately 40.31 million Hong Kong dollars net.
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.

China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.

SUNSHINE OIL (02012) plans to discount about 10% of the rights issue, raising a maximum of approximately 40.31 million Hong Kong dollars net.






